Your browser doesn't support javascript.
loading
Adverse Event Reporting in Cancer Clinical Trials: Incorporating Patient-Reported Methods. A Systematic Scoping Review.
Grahvendy, Minna; Brown, Bena; Wishart, Laurelie R.
Afiliação
  • Grahvendy M; Cancer Trials Unit, Princess Alexandra Hospital, Queensland Health, Brisbane, QLD, 4102, Australia. minna.grahvendy@health.qld.gov.au.
  • Brown B; School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, QLD, Australia. minna.grahvendy@health.qld.gov.au.
  • Wishart LR; Southern Queensland Centre of Excellence in Aboriginal and Torres Strait, Islander Primary Health Care, Metro South Health, Brisbane, QLD, Australia.
Patient ; 17(4): 335-347, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38589749
ABSTRACT
BACKGROUND AND

OBJECTIVE:

The history of clinical trials is fraught with unethical practices. Since 1945, robust frameworks have evolved to standardise the collection and reporting of safety data, most notably, the Common Terminology Criteria for Adverse Events (CTCAE) from the National Cancer Institute; used by investigators to report side effects experienced by participants. As medicine moves into the patient-centred model, interest has been growing to collect data on adverse events directly from participants (patient-reported adverse events). The aim of this systematic scoping review was to investigate the inclusion of patient-reported adverse event data within safety/tolerability analyses and explore the collection and reporting of patient-reported adverse event data. METHODS AND

RESULTS:

A database search was undertaken and the Covidence platform was used to manage the review; results were analysed descriptively. Sixty-eight studies were included in the analysis. An increase in the number of studies that incorporate patient-reported adverse event data was seen by year. Seventy instruments were used for the collection of patient-reported adverse event data with recall period, mode, frequency and site of administration varying across studies; the duration of data collection ranged from 28 days to 6 years. Frequently, information on these details was omitted from publications. The number of instruments used by studies to collect patient-reported adverse event data ranged from one to seven instruments.

CONCLUSIONS:

Despite growing calls for the inclusion of patient-reported adverse events, this has not yet translated into published reports. The collection and reporting of these data were variable and conducted using instruments that were not designed for purpose. To address these inconsistencies, standardisation of data collection and reporting using a purpose-built validated instrument is required.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medidas de Resultados Relatados pelo Paciente / Neoplasias Limite: Humans Idioma: En Revista: Patient / Patient (Online) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália País de publicação: Nova Zelândia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medidas de Resultados Relatados pelo Paciente / Neoplasias Limite: Humans Idioma: En Revista: Patient / Patient (Online) Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Austrália País de publicação: Nova Zelândia